PET-CT阴性时是否还需活检对侧肺门N3淋巴结进行EBUS分期?
该单中心回顾性队列纳入1737例临床影像T1-3、N0-3、M0非小细胞肺癌患者行系统EBUS分期,其中1567例肺门N3 PET-CT阴性,739例EBUS下淋巴结增大并采样。肺门N3恶性比例仅0.68%(95%CI 0.22%-1.57%),显著低于预设5%阈值(P<.001)。纵隔N3 PET阳性者隐匿肺门N3转移风险更高(6.5%,3/46,P=.003)。作者认为中度镇静下时间有限时,若肺门及纵隔N3 PET均阴性,可先从纵隔N3开始;纵隔N3 PET阳性者可能应采样肺门N3。
要点
- PET-CT肺门N3阴性者中,EBUS采样肺门N3恶性比例仅0.68%(5/739,95%CI 0.22%-1.57%),显著低于5%阈值(P<.001)。
- 纵隔N3 PET阳性者隐匿肺门N3转移比例6.5%(3/46,95%CI 1.4%-17.9%),风险显著更高(P=.003)。
- 中度镇静下时间有限时,若肺门及纵隔N3 PET均阴性,可先从纵隔N3开始EBUS分期。
- 纵隔N3 PET阳性者可能应进行肺门N3采样,以检出隐匿转移。
- 该结论来自单中心回顾性队列,需前瞻性验证后方可作为常规决策依据。
适用人群与场景
- 连续纳入的临床影像T1-3、N0-3、M0非小细胞肺癌患者,行系统EBUS分期并采样PET-CT阴性的肺门N3淋巴结。
- 排除人群原文未提及。
- 场景为EBUS分期操作,使用中度镇静。
诊断标准与关键阈值
- 系统EBUS分期顺序:从肺门N3开始,依次至纵隔N3、N2、N1,并采样所有增大淋巴结(大小≥5 mm)。
- 专家意见设定恶性概率阈值<5%足以跳过肺门N3淋巴结采样。
- 采用二项精确检验比较观察比例与5%阈值概率。
处置流程与药物剂量
- 第一步:若肺门及纵隔N3淋巴结PET-CT均阴性,中度镇静下时间有限时,可先从纵隔N3淋巴结开始EBUS分期。
- 第二步:若纵隔N3淋巴结PET-CT阳性,可能应进行肺门N3淋巴结采样。
- 药物剂量、途径、频次及疗程原文未提及。
红旗征与不能漏的情况
- 纵隔N3淋巴结PET-CT阳性者隐匿肺门N3转移风险更高(6.5%,3/46),原文建议可能应采样肺门N3。
- 原文未提及其他需立刻处理或不能漏诊的情况。
研究设计与关键结果
- 研究类型:回顾性观察性单中心队列研究。
- 样本量与中心数:1737例连续患者行EBUS分期,单中心;1567例肺门N3 PET-CT阴性,其中739例EBUS下淋巴结增大并采样。
- 人群:临床影像T1-3、N0-3、M0非小细胞肺癌。
- 干预与对照:系统EBUS分期并采样PET-CT阴性的肺门N3淋巴结,无对照。
- 主要终点:肺门N3恶性比例0.68%(5/739,95%CI 0.22%-1.57%),显著低于5%阈值(P<.001)。
- 关键次要终点:纵隔N3 PET阳性者肺门N3隐匿转移6.5%(3/46,95%CI 1.4%-17.9%),风险更高(P=.003)。
- 不良事件原文未提及。
证据类型、等级与局限
- 证据类型:回顾性观察性单中心队列研究。
- 证据等级或推荐强度:原文未提及。
- 局限:单中心、回顾性设计;原文未提及其他局限。
对床旁实践的改变
- 可改变EBUS分期起始顺序:PET-CT肺门及纵隔N3均阴性时,中度镇静下可先从纵隔N3开始,以节省时间。
- 纵隔N3 PET阳性者应考虑加采肺门N3,以检出约6.5%的隐匿转移。
- 适用人群为临床影像T1-3、N0-3、M0非小细胞肺癌行EBUS分期者;不适用人群原文未提及。
- 常见陷阱:该结论来自单中心回顾性研究,不能将0.68%或6.5%直接作为所有人群的决策阈值,需前瞻性验证。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Systematic endobronchial ultrasound (EBUS)-guided lung cancer staging starts with hilar N3 nodes, proceeding sequentially to mediastinal N3, N2, and N1 nodes, with sampling of all enlarged nodes (size, ≥ 5 mm) by EBUS. However, procedure time is limited by patient comfort when moderate sedation is used. It is unclear if EBUS staging should start with hilar N3 nodes or whether starting with mediastinal N3 nodes suffices. Knowing the probability of hilar N3 nodes with PET-CT scan negative findings harboring occult metastasis can inform this decision.
RESEARCH QUESTION: What proportion of patients with hilar N3 nodes showing negative PET-CT scan findings have malignancy by EBUS?
STUDY DESIGN AND METHODS: This retrospective observational, single-center cohort study included consecutive patients with clinical-radiographic T1-3, N0-3, M0 non-small cell lung cancer undergoing systematic EBUS staging with biopsy of hilar N3 nodes with negative PET-CT scan findings. The primary outcome was the proportion of patients with malignant hilar N3 nodes showing negative PET-CT scan findings. Based on expert opinion, a threshold probability of malignancy of less than 5% was considered sufficient to skip hilar N3 nodes. We used the binomial exact test to compare the observed proportion vs threshold probability of 5%.
RESULTS: Of 1,737 consecutive patients undergoing EBUS staging, 1,567 showed negative PET-CT scan findings of the hilar N3 nodes. These nodes were enlarged by EBUS and were sampled in 739 patients. Malignancy was found in the hilar N3 nodes of 5 of 739 patients (0.68%; 95% CI, 0.22%-1.57%). The proportion was significantly less than the threshold probability (P < .001). Patients with positive PET scan results of the mediastinal N3 nodes were at higher risk of having occult hilar N3 nodal metastasis (P = .003), found in 3 of 46 patients (6.5%; 95% CI, 1.4%-17.9%) with positive PET scan results of the mediastinal N3 nodes.
INTERPRETATION: When using moderate sedation, because time is limited, it is reasonable to start with the mediastinal N3 nodes if the hilar and mediastinal N3 nodes show negative PET scan results. Patients with positive PET scan findings of the mediastinal N3 nodes probably should undergo hilar N3 node sampling.
参考来源
- Sainz Zúñiga PV, Martinez-Zayas G, Molina S, et al. Is Biopsy of Contralateral Hilar N3 Lymph Nodes With Negative PET-CT Scan Findings Necessary When Performing Endobronchial Ultrasound Staging? Chest. 2020. PMID: 33393471. doi:10.1016/j.chest.2020.10.041
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。